1 |
Azakir BA, Di Fulvio S, Salomon S, Brockhoff M, Therrien C, Sinnreich M. Modular dispensability of dysferlin C2 domains reveals rational design for mini-dysferlin molecules. J Biol Chem 2012;287:27629-27636.
DOI
|
2 |
Herson S, Hentati F, Rigolet A, Behin A, Romero NB, Leturcq F, et al. A phase I trial of adeno-associated virus serotype 1- -sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain 2012;135:483-492.
DOI
ScienceOn
|
3 |
Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, et al. Sustained -sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 2010;68:629-638.
DOI
ScienceOn
|
4 |
Buj-Bello A, Fougerousse F, Schwab Y, Messaddeq N, Spehner D, Pierson CR, et al. AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis. Hum Mol Genet 2008;17:2132-2143.
DOI
ScienceOn
|
5 |
Johnson NE, Heatwole CR. Myotonic dystrophy: from bench to bedside. Semin Neurol 2012;32:246-254.
DOI
ScienceOn
|
6 |
Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012;488:111-115.
DOI
ScienceOn
|
7 |
Chanchlani N. Muscular dystrophy patients could live extra 15 years, if care standards implemented. BMJ 2010;340:c3055.
DOI
|
8 |
Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011;12:341-355.
|
9 |
Maguire AM, Simonelli F, Pierce EA, Pugh EN, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Eng J Med 2008;358:2240-2248.
DOI
ScienceOn
|
10 |
Flemming A. Regulatory watch: pioneering gene therapy on brink of approval. Nat Rev Drug Discov 2012;11:664.
|
11 |
Moulton HM. In vivo delivery of morpholino oligos by cellpenetrating peptides. Curr Pharm Des 2012;epub.
|
12 |
Shin J-H, Yue Y, Duan D. Recombinant adeno-associated viral vector production and purification. Methods Mol Biol 2012;798:267-284.
|
13 |
Wasala NB, Shin J-H, Duan D. The evolution of heart gene delivery vectors. J Gene Med 2011;13:557-565.
DOI
ScienceOn
|
14 |
Scott JM, Li S, Harper SQ, Welikson R, Bourque D, DelloRusso C, et al. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscul Disord 2002;12:S23-29.
DOI
|
15 |
Liu M, Yue Y, Harper SQ, Grange RW, Chamberlain JS, Duan D. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther 2005;11:245-256.
DOI
|
16 |
Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006;12:787-789.
DOI
ScienceOn
|
17 |
Shin J-H, Nitahara-Kasahara Y, Hayashita-Kinoh H, Ohshima-Hosoyama S, Kinoshita K, Chiyo T, et al. Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction. Gene Ther 2011;18:910-919.
DOI
ScienceOn
|
18 |
Bostick B, Shin J-H, Yue Y, Wasala NB, Lai Y, Duan D. AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy. J Mol Cell Cardiol 2012;53:217-222.
DOI
ScienceOn
|
19 |
Shin J-H, Yue Y, Srivastava A, Smith B, Lai Y, Duan D. A simplified immune suppression scheme leads to persistent microdystrophin expression in duchenne muscular dystrophy dogs. Hum Gene Ther 2012;23:202-209.
DOI
ScienceOn
|
20 |
Bowles DE, McPhee SWJ, Li C, Gray SJ, Samulski JJ, Camp AS, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2012;20:443-455.
DOI
ScienceOn
|
21 |
Vulin A, Barthélémy I, Goyenvalle A, Thibaud J-L, Beley C, Griffith G, et al. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther 2012;20:2120-2133.
DOI
ScienceOn
|
22 |
Odom GL, Gregorevic P, Allen JM, Chamberlain JS. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol Ther 2011;19:36-45.
DOI
ScienceOn
|
23 |
Bartel MA, Weinstein JR, Schaffer DV. Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther 2012;19:694-700.
DOI
ScienceOn
|
24 |
Aartsma-Rus A, Singh KHK, Fokkema IFAC, Ginjaar IB, Van Ommen G-J, Den Dunnen JT, et al. Therapeutic exon skipping for dysferlinopathies? Eur J Hum Genet 2010;18:889-894.
DOI
ScienceOn
|
25 |
Grose WE, Clark KR, Griffin D, Malik V, Shontz KM, Montgomery CL, et al. Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS One 2012;7:e39233.
DOI
|
26 |
Meryon E. On granular and fatty degeneration of the voluntary muscles. Med Chir Trans 1852;35:73-84.1.
|
27 |
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93.
DOI
ScienceOn
|
28 |
Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Nat Acad Sci USA 1993;90:3710-3714.
DOI
ScienceOn
|
29 |
Aartsma-Rus A. Overview on DMD exon skipping. Methods Mol Biol 2012;867:97-116.
|
30 |
Aartsma-Rus A, Van Deutekom JCT, Fokkema IF, Van Ommen G-JB, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006;34:135-144.
DOI
ScienceOn
|
31 |
Aartsma-Rus A. Overview on AON design. Methods Mol Biol 2012;867:117-129.
|
32 |
Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003;31:3568-3571.
DOI
ScienceOn
|
33 |
Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an openlabel, phase 2, dose-escalation study. Lancet 2011;378:595-605.
DOI
ScienceOn
|
34 |
Goemans NM, Tulinius M, Van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Eng J Med 2011;364:1513-1522.
DOI
ScienceOn
|
35 |
Mendell J, Rodio-Klapac L, Sahenk Z, Roush K, Bird L, Lowes L, et al. Results at 48 weeks of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with Duchenne muscular dystrophy. 17th International Congress of the World Muscle Society. Perth, Australia; 2012.
|
36 |
Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, Van Deutekom J, Van Ommen G-J, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009;30:293-299.
DOI
ScienceOn
|
37 |
Muntoni F. The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009. Neuromuscul Disord 2010;20:355-362.
DOI
ScienceOn
|
38 |
Townsend D, Yasuda S, Li S, Chamberlain JS, Metzger JM. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 2008;16:832-835.
DOI
ScienceOn
|
39 |
Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002;12:926-929.
DOI
ScienceOn
|
40 |
Malerba A, Boldrin L, Dickson G. Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. Nucleic Acid Ther 2011;21:293-298.
DOI
ScienceOn
|
41 |
Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928.
DOI
|
42 |
Sheridan C. Gene therapy finds its niche. Nat Biotech 2011;29:121-128.
DOI
|
43 |
Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009;461:272-276.
DOI
|
44 |
Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid -glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68:99-109.
DOI
ScienceOn
|
45 |
Van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Eng J Med 2010;362:1396-1406.
DOI
ScienceOn
|